COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders19/05/2025
-   
  aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference19/05/2025
-   
  STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Reimbursement of 308nm Excimer Laser Treatments, Unlocking Access for Millions with Inflammatory and Auto-Immune Skin Diseases19/05/2025
-   
  Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value19/05/2025
-   
  Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital19/05/2025
-   
  SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology19/05/2025
-   
  Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting19/05/2025
-   
  Transactions under Novonesis’ share buyback program19/05/2025
-   
  Reunion Neuroscience Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)19/05/2025
-   
  Atsena Therapeutics Announces Positive Clinical Data from Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy to Treat X-linked Retinoschisis (XLRS)19/05/2025
-   
  Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)19/05/2025
-   
  Lifeward to Present at Sidoti Virtual Investor Conference on May 2119/05/2025
-   
  Rejuvenate Biomed Doses First Patient in Phase 2 Trial on COPD-related Muscle Weakness and Sarcopenia19/05/2025
-   
  Trading in GN Store Nord shares by board members, executives and associated persons19/05/2025
-   
  Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab19/05/2025
-   
  Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-203119/05/2025
-   
  Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes19/05/2025
-   
  Trading in GN Store Nord shares by board members, executives and associated persons19/05/2025
-   
  Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures19/05/2025
Pages